Benzinga | Dec 9, 2021 09:51PM EST

Where Bristol-Myers Squibb Stands With Analysts

Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish BearishTotal Ratings 1 1 4 0 0Last 30D 0 0 1 0 01M Ago 0 1 0 0 02M Ago 1 0 2 0 03M Ago 0 0 1 0 0

According to 6 analyst offering 12-month price targets in the last 3 months, Bristol-Myers Squibb has an average price target of $66.83 with a high of $72.00 and a low of $58.00.

Below is a summary of how these 6 analysts rated Bristol-Myers Squibb over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average has decreased by 6.2% from the previous average price target of $71.25.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.